Brain histamine H₁ receptor occupancy after oral administration of desloratadine and loratadine

Abstract

Some histamine H 1 receptor (H 1 R) antagonists induce adverse sedative reactions caused by blockade of histamine transmission in the brain. Desloratadine is a second‐generation antihistamine for treatment of allergic disorders. Its binding to brain H 1 Rs, which is the basis of sedative property of antihistamines, has not been examined previously in the human brain by positron emission tomography (PET). We examined brain H 1 R binding potential ratio (BPR), H 1 R occupancy (H 1 RO), and subjective sleepiness after oral desloratadine administration in comparison to loratadine. Eight healthy male volunteers underwent PET imaging with [ 11 C]‐doxepin, a PET tracer for H 1 Rs, after a single oral administration of desloratadine (5 mg), loratadine (10 mg), or placebo in a double‐blind crossover study. BPR and H 1 RO in the cerebral cortex were calculated, and plasma concentrations of loratadine and desloratadine were measured. Subjective sleepiness was quantified by the Line Analogue Rating Scale (LARS) and the Stanford Sleepiness Scale (SSS). BPR was significantly lower after loratadine administration than after placebo (0.504 ± 0.074 vs 0.584 ± 0.059 [mean ± SD], P < 0.05), but BPR after desloratadine administration was not significantly different from BPR after placebo (0.546 ± 0.084 vs 0.584 ± 0.059, P = 0.250). The plasma concentration of loratadine was negatively correlated with BPR in subjects receiving loratadine, but that of desloratadine was not correlated with BPR. Brain H 1 ROs after desloratadine and loratadine administration were 6.47 ± 10.5% and 13.8 ± 7.00%, respectively ( P = 0.103). Subjective sleepiness did not significantly differ among subjects receiving the two antihistamines and placebo. At therapeutic doses, desloratadine did not bind significantly to brain H 1 Rs and did not induce any significant sedation.

Calcium and Neural Stem Cell Proliferation

“…Histamine PEA [103], Beta-histine [104], Histaprodifen [105], 2-TEA [106] Diphenhydramine, Pyrilamine [106], Chlorpheniramine, Mepyramine [107], Promethazine [108], Cetirizine [109], Hydroxyzine [110], Clemastine [111], Loratadine, Desloratadine [112], Fexofenadine, Levocetirizine [113], Azelastine, Acrivastine, Astemizole, Ebastine, Fexodenadine, Ketotifen, Mizolastine, Terfenadine [114] ADRα-1AR (adrenergic α1receptor)…”

Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors against Resistance

“…Dual/multiple inhibition has been supposed to be an efficient way to overcome drug resistance. − Different from drug combination (more detailed discussion in section ), a dual/multiple ligand is designed to target two or several targets related to the same disease (Figure ) but not two/several agents targeting various targets. The targets may act as upstream/downstream (e.g., A674563 targeting AKT/FLT3 in acute myeloid leukemia) or two individual functions/pathways (e.g., aripiprazole targeting both D 2 and 5-HT 1A in psychosis), and especially abundant achievement has been obtained from the following famous multiple inhibition, including fluoxetine targeting SERT5-HT1A/5-HT1D/Alpha2/DAT/NK1 in depression, , loratadine targeting H1-5LO/B2/H3/NK1/PAF/TxA2 in allergy, and rivastigmine targeting AChE-SERT/MAO in Alzheimer’s disease. , …”

Efficacy and Safety for Use Desloratadine in Children with Allergic Conditions (Literature Review, Own Research)

“…Доведено, що дезлоратадин як препарат ІІ покоління не викликає седативних реакцій, що спричинені блокадою передачі гістаміну в мозку [34].…”